Results 11 to 20 of about 11,301 (165)
Swiss Medical Weekly, 2015 The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces LDL receptor recycling, leading to a decrease of low-density lipoprotein cholesterol (LDL-
Baris Gencer +2 more
doaj +7 more sources
Cell, 2016 Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Pradeep, Natarajan, Sekar, Kathiresan
+6 more sources
Inadequate Response to PCSK9 Inhibitors. [PDF]
JACC Case RepSuboptimal response to various proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapies has been reported in the literature; however, inadequate response to proprotein convertase subtilisin/kexin type 9 monoclonal antibodies and small interference RNA is rare to our knowledge.A 68-year-old woman with hypercholesterolemia (baseline low-
Bimal T +7 more
europepmc +3 more sources
Naturally Occurring PCSK9 Inhibitors [PDF]
Nutrients, 2020 Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotein (LDL) cholesterol levels.
Maria Pia Adorni +4 more
openaire +5 more sources
Hepatology, EarlyView., 2022 Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince +30 more
wiley +1 more source
Biomedicine & Pharmacotherapy, 2022 annually in Europe, 4 million people die from cardiovascular diseases, the main cause of which is atherosclerosis. In order to slow down the development of atherosclerotic plaques, the main therapeutic goal is to lower LDL cholesterol (LDL-C) level. Undoubtedly, statins are the basis of lipid-lowering therapy for many years.
Grzegorz, Grześk +6 more
openaire +2 more sources
PCSK9 inhibitors for hypercholesterolaemia [PDF]
BMJ, 2017 New drugs, old problems Statins (hydroxymethyl-glutaryl coenzyme A reductase inhibitors) reduce “bad” low density lipoprotein (LDL) cholesterol concentrations and cardiovascular risk. So too, do better diet and more exercise, which together almost halve rates of coronary event rates when compared with an “unfavourable lifestyle.”3 For some people ...
Patricia, McGettigan, Robin E, Ferner
openaire +2 more sources
PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
Рациональная фармакотерапия в кардиологии, 2022 Aim. To characterize patients receiving PCSK9 inhibitors, and assess the efficiency of their treatment in a specialized lipid center.Material and methods.
A. V. Blokhina +5 more
doaj +1 more source
Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. [PDF]
PLoS ONE, 2017 The introduction of Proprotein covertase subtilisin/kexin type 9 (PCSK9) inhibitors has been heralded as a major advancement in reducing low-density lipoprotein cholesterol levels by nearly 50%.
Alejandro Arrieta +3 more
doaj +1 more source
The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
Journal of Education, Health and Sport, 2023 Introduction and aim. Cardiovascular diseases are the main cause of mortality in the world. One of the alterable risk factors of ischaemic heart disease is dyslipidemia.
Natalia Ilnicka +4 more
doaj +1 more source